Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

@article{Citrome2009AsenapineFS,
  title={Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.},
  author={Leslie Citrome},
  journal={International journal of clinical practice},
  year={2009},
  volume={63 12},
  pages={
          1762-84
        }
}
OBJECTIVE To describe the efficacy and safety of asenapine for the treatment of schizophrenia and bipolar disorder. DATA SOURCES The pivotal registration trials were accessed by querying http://www.pubmed.gov, http://www.fda.gov and http://www.clinicaltrials.govfor the search terms 'asenapine' or 'ORG 5222'. STUDY SELECTION All available clinical reports of studies were identified, as well as preclinical animal and receptor affinity studies that describe potential mechanisms of action… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Asenapine for bipolar disorder

  • Neuropsychiatric disease and treatment
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Role of sublingual asenapine in treatment of schizophrenia

  • Neuropsychiatric disease and treatment
  • 2011
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND

A Review of Asenapine in the Treatment of Bipolar Disorder

  • Clinical Drug Investigation
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND